2023 World Conference on Lung Cancer (Posters)-EP11.02. Rh-endostatin Combined With PD-1 inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC

EP11.02. Rh-endostatin Combined With PD-1 inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC - PDF(Slides)

Back to course

Pdf Summary

A study conducted in China investigated the efficacy and safety of combining recombinant human endostatin (Rh-endostatin) with PD-1 inhibitors and chemotherapy as the first-line treatment for non-squamous non-small cell lung cancer (NSCLC) in patients negative for EGFR/ALK mutations. Endostatin is known to normalize tumor blood vessels and modulate the immune microenvironment. The study was an open-label, multicenter, phase II, prospective cohort study conducted at 16 research centers in China.<br /><br />The study included patients aged 18 to 75 with stage IIIB, IIIC, or IV non-squamous NSCLC, an ECOG performance status of 0 or 1, and no previous systemic treatment. The primary endpoints of the study were objective response rate (ORR) and progression-free survival (PFS), while the secondary endpoint was overall survival (OS).<br /><br />Two cohorts were evaluated in the study. Cohort 1 received Rh-endostatin, PD-1 inhibitors, and standard chemotherapy for up to 4-6 cycles, followed by maintenance Rh-endostatin plus PD-1 inhibitor. Cohort 2 received Rh-endostatin and standard chemotherapy for up to 4-6 cycles, followed by maintenance Rh-endostatin. The ORR was 57.7% in cohort 1 and 34.2% in cohort 2. The disease control rate (DCR) was 88.5% in cohort 1 and 84.2% in cohort 2. The median PFS was 16.7 months in cohort 1 and 16.4 months in cohort 2.<br /><br />Overall, the combination of Rh-endostatin, PD-1 inhibitors, and chemotherapy demonstrated favorable clinical outcomes and a tolerable toxicity profile as a first-line treatment for EGFR/ALK-negative, advanced or metastatic, non-squamous NSCLC. The study also reported the incidences of adverse events (AEs), with an overall incidence of AEs of any grade being 80.8% in cohort 1 and 81.6% in cohort 2. No treatment-related deaths occurred. The most commonly reported treatment-related adverse events were anemia, nausea, decreased white blood cell count, decreased neutrophil count, vomiting, and abnormal liver function.<br /><br />The study was funded by the Science and Technology Innovation Capability Improvement Project of Army Medical University. The authors acknowledged the patients, their families, investigators, and medical staff involved in the study.

Asset Subtitle

Dong Wang

Meta Tag

Speaker Dong Wang

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

China

efficacy

safety

endostatin

PD-1 inhibitors

chemotherapy

non-small cell lung cancer

EGFR/ALK mutations

tumor blood vessels

immune microenvironment